Progestin Induced Secondary Diabetes Mellitus And Adrenal Insufficiency: A Case Report

Min Lu,Shiyi Lv,Sisi Xi,Xing Chen,Zhenfang Yuan,Yang Zhang,Wenpei Bai,Yimin Cui
2016-01-01
Abstract:We report a case of 34-year-old woman diagnosed as atypical endometrial hyperplasia and was administered megestrol acetate (MA) 160 mg qd. One month later, she presented palpitation, sweating, tremor, head pain and body weight gain (4 kg within a month). After 3 months treatment, her symptoms above worsened and weight gain continued (22 kg within 4 month). We altered the treatment regimen to medroxyprogesterone acetate (MPA) 500 mg daily oral but symptoms gradually worsened. Laboratory studies showed cortisol (ug/dl) and adreno-corticotropic-hormone (ACTH, pg/ml) rhythm as: 8 a.m. 2.03; 23.04; 4 p.m. 0.27; 2.72; 0 a.m. 0.19; 1.95; Extended oral glucose tolerance test (OGTT, mmol/L) as: 0 h 4.59; 0.5 h 8.86; 1 h 9.83; 2 h 11.3; 3 h 7.21; 4 h 3.95; 4.5 h 2.5. After endometrial curettage, we treated her with acarbose 50 mg tid and pioglitazone 15 mg qd, as well as MPA 500 mg qd for 3 months, the blood glucose level of the patient was under control and menstrual cycle was regular. Clinicians should be aware of the potential effects of progestin on the hypothalamic-pituitary-adrenal (HPA) axis and glucose tolerance.
What problem does this paper attempt to address?